Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Study suggests neutralizing SARS-CoV-2 antibodies offer protection against reinfection

A new study published in November 2020 on the preprint server medRxiv* indicates that the chances of symptomatic infection are indeed much lower among the population with antibodies to the virus.

22 Nov 2020

Anti-SARS-CoV-2 hyperimmune globulin produced from convalescent plasma pool has 3-fold antibody neutralizing activity

In a recent study published in the preprint server bioRxiv, researchers from the Grifols Bioscience Research Group reported on the collection of convalescent plasma and production of anti-SARS-CoV-2 hyperimmune globulin for use in clinical research.

22 Nov 2020

UVA researchers discover gene responsible for the metastasis of triple-negative breast cancer

University of Virginia Cancer Center researchers have identified a gene responsible for the spread of triple-negative breast cancer to other parts of the body - a process called metastasis - and developed a potential way to stop it.

20 Nov 2020

Scientists explain potential reasons for SARS-CoV-2 re-infection

A study, which was published in the journal New Microbes and New Infections, focused on the possible reasons for SARS-CoV-2 reinfection.

20 Nov 2020

Multi-institution team receives prestigious award for breakthrough research on SARS-CoV-2

The Association for Computing Machinery (ACM) awarded its first ACM Gordon Bell Special Prize for High Performance Computing-Based COVID-19 Research to a multi-institution research team that included the U.S. Department of Energy's (DOE) Argonne National Laboratory.

20 Nov 2020

Scientists develop a new vaccine approach for HIV

Unlike so many other deadly viruses, HIV still lacks a vaccine. The virus--which continues to infect millions around the world--has proven especially tricky to prevent with conventional antibodies, in part because it evolves so rapidly in the body.

20 Nov 2020

Genetic modification in ‘coat’ of fatal brain virus may allow it to escape antibodies

A genetic modification in the 'coat' of a brain infection-causing virus may allow it to escape antibodies, according to Penn State College of Medicine researchers.

20 Nov 2020

Sinovac Biotech's COVID-19 vaccine candidate triggers immune response

Now, Sinovac Biotech's candidate vaccine, CoronaVac, has been found to induce an immune response in healthy adults aged 18–59 years, 28 days post-vaccination. However, the level of antibodies generated was lower than in people who had recovered from the illness.

19 Nov 2020

Antibody combinations may be more effective at preventing, treating COVID-19

Pairs of antibodies may be more effective than single antibodies at preventing and treating COVID-19, according to a new study by researchers at the University of North Carolina at Chapel Hill and The Rockefeller University in New York.

19 Nov 2020

Mosaic RBD nanoparticles elicit neutralizing antibodies against SARS-CoV-2

The researchers show that the mice immunized with homotypic or mosaic nanoparticles produced broad binding and neutralizing responses, in contrast to plasma antibodies elicited in humans by SARS-CoV-2 infection. The RBD nanoparticles induced cross-reactive IgG responses in the immunized mice.

19 Nov 2020

New findings support current and planned clinical trials of Janssen SARS-CoV-2 vaccine

Researchers from the United States and The Netherlands have conducted a pre-clinical study supporting the initiation of a Phase 3 trial to test a two-dose regimen of the Janssen Ad26.COV2.S vaccine candidate among adult and elderly individuals.

19 Nov 2020

Seroprevalence meta-analysis predicts 643 million already infected by SARS-CoV-2 globally

A recent systematic review and meta-analysis conducted by a team of international scientists reveal low seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in the general population.

19 Nov 2020

Detectable SARS-CoV-2 antibodies 120 days post-infection in Chicago case study

In a recent study, a team of researchers at Northwestern University, USA, had found that nearly 20 percent seroprevalence in the United States metropolitan site, Chicago, over the summer, during a period when lockdown restrictions were eased. They found that three-quarters of seropositive individuals retained detectable antibodies for at least 120 days or four months.

19 Nov 2020

SARS-CoV-2 immunity can last over six months, study finds

US-based scientists have released a study on preprint server bioRxiv*, titled “Immunological memory to SARS-CoV-2 assessed for greater than six months after infection,” contributing to the enormous research effort currently underway in this area.

19 Nov 2020

UK’s COVID-19 vaccine shows similar safety and immunogenicity results in healthy older adults

The UK's vaccine against SARS-CoV-2 shows similar safety and immunogenicity results in healthy older adults (aged 56 years and over) to those seen in adults aged 18-55 years.

19 Nov 2020

Randomized trial adds new evidence to effectiveness of wearing masks

Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information.

19 Nov 2020

Alzheimer's study shows tau protein changes according to dementia stage

Research into Alzheimer's disease has long focused on understanding the role of two key proteins, beta amyloid and the tau protein. Found in tangles in patients' brain tissue, a pathological form of the tau protein contributes to propagating the disease in the brain.

19 Nov 2020

Most COVID-19 convalescent individuals have long-lasting memory T cell responses

Recently, researchers from the Huazhong University of Science and Technology, China, and the University of Duisburg-Essen, Germany, conducted a comprehensive analysis of memory T cell responses against SARS-CoV-2 in individuals who have recovered from COVID-19.

18 Nov 2020

New understanding of glycan signatures of the SARS-COV-2 S1 spike protein

A team of scientists from the University of Oxford, UK, has revealed that site-specific glycosylation differs between spike proteins derived from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a viral vector-based vaccine candidate.

18 Nov 2020

"Escape mutations" could help SARS-CoV-2 evade immune attack

Researchers in the United States have identified mutations within severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – that can reduce antibody binding to the virus, potentially mediating its escape from immune attack.

18 Nov 2020

Antibody News and Research

Further Reading

Study suggests neutralizing SARS-CoV-2 antibodies offer protection against reinfection

Anti-SARS-CoV-2 hyperimmune globulin produced from convalescent plasma pool has 3-fold antibody neutralizing activity

UVA researchers discover gene responsible for the metastasis of triple-negative breast cancer

Scientists explain potential reasons for SARS-CoV-2 re-infection

Multi-institution team receives prestigious award for breakthrough research on SARS-CoV-2

Scientists develop a new vaccine approach for HIV

Genetic modification in ‘coat’ of fatal brain virus may allow it to escape antibodies

Sinovac Biotech's COVID-19 vaccine candidate triggers immune response

Antibody combinations may be more effective at preventing, treating COVID-19

Mosaic RBD nanoparticles elicit neutralizing antibodies against SARS-CoV-2

New findings support current and planned clinical trials of Janssen SARS-CoV-2 vaccine

Seroprevalence meta-analysis predicts 643 million already infected by SARS-CoV-2 globally

Detectable SARS-CoV-2 antibodies 120 days post-infection in Chicago case study

SARS-CoV-2 immunity can last over six months, study finds

UK’s COVID-19 vaccine shows similar safety and immunogenicity results in healthy older adults

Randomized trial adds new evidence to effectiveness of wearing masks

Alzheimer's study shows tau protein changes according to dementia stage

Most COVID-19 convalescent individuals have long-lasting memory T cell responses

New understanding of glycan signatures of the SARS-COV-2 S1 spike protein

"Escape mutations" could help SARS-CoV-2 evade immune attack

How to make hybridoma-based antibody discovery more efficient eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo